Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.

Cancers (Basel) · 2023 · PMC10650115 · PMID 37958395

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

The comparison of the RFS between the group treated with ablation therapy during conversion therapy and the liver resection group showed a slight trend toward a longer RFS in the liver resection group, but the difference was not significant (ablation group, 274 days [157–NA]; hepatectomy group, NA days [447–NA]; p = 0.09; Figure S3b ).

also in 1,563 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.